To evaluate the influence of the dose of co-trimoxazole prophylaxis on the risk of toxoplasmosis in human immunodeficiency virus (HIV)-infected patients, we performed a nested case-control study of 32 patients with toxoplasmosis (case patients) and 64 patients without toxoplasmosis (control patients) who were matched by CD4 cell count and Toxoplasma gondii serostatus; these patients were from a cohort of 521 HIV-infected patients who underwent a diagnostic neuroimaging study between March 1993 and January 1997. Twenty-seven (84.4%) of 32 case patients and 33 (51.6%) of 64 control patients received low doses of co-trimoxazole, a finding associated with an adjusted odds ratio (OR) of 9.36 (95% confidence interval [CI], 2.05-42.75) and indicating 89% protective efficacy for high doses. Fifteen (46.9%) of 32 case patients and 16 (25%) of 64 control patients were exposed to rifampin (adjusted OR, 3.38; 95% CI, 1.08-10.61). These results indicate that high doses of co-trimoxazole appear to be more effective than low doses for lowering the risk of toxoplasmosis in HIV-infected patients and that rifampin therapy may reduce the efficacy of co-trimoxazole.
Trimethoprim-sulfamethoxazole (co-trimoxazole) is the drug of choice for dual prophylaxis for Pneumocystis carinii pneumonia and toxoplasmosis [1, 2] . Doses ranging from 1 doublestrength (DS) tablet (containing 160 mg of trimethoprim and 800 mg of sulfamethoxazole) twice daily (i.e., 14 DS tablets per week) to 1 DS tablet 3 times weekly (i.e., 3 DS tablets per week) have been used [3, 4] . Although to our knowledge no prospective randomized trials have been specifically designed to evaluate the efficacy of co-trimoxazole as primary prophylaxis for toxoplasmic encephalitis in Toxoplasma-seropositive patients with advanced HIV infection, clinical data suggest that cotrimoxazole at the doses used in prophylaxis for P. carinii pneumonia may be effective [2] [3] [4] . However, the best co-trimoxazole regimen has not yet been established.
At the beginning of 1990, the policy of our hospital concerning prophylaxis for P. carinii infection and Toxoplasma gondii infection consisted of 1 DS tablet of co-trimoxazole twice daily 3 days per week (i.e., 6 DS tablets per week); this regimen was recommended for all HIV-infected patients with CD4 lymphocyte counts ! /L. In 1991-1992, several studies 6 200 ϫ 10 [5] [6] [7] [8] [9] showed that lower doses could be equally effective and better tolerated. Therefore, from 1992 on, decisions regarding the prophylactic regimen for individual patients left to the discretion of the treating staff physicians. Since then, our patients have received 1 of the following 5 prophylactic regimens: 1 DS tablet daily, 2 DS tablets daily 3 times weekly, 1 DS tablet 5 times weekly, 1 DS tablet 3 times weekly, and 1 single-strength (SS) tablet daily. There were no established criteria for prescribing any of the regimens, although most patients of each doctor received the same prophylaxis. We had the impression that from the time that doctors began prescribing low doses of co-trimoxazole, the number of patients receiving co-trimoxazole prophylaxis who developed toxoplasmosis increased. Therefore, we planned a study to assess the efficacy of the various doses of co-trimoxazole that are used in our hospital against P. carinii pneumonia as primary prophylaxis for toxoplasmic encephalitis.
At the beginning of 1993, 1 patient who was receiving low doses of co-trimoxazole and rifampin developed brain toxoplasmosis. This prompted us to study potential interactions between these drugs, even though to our knowledge no such interactions had been described in the literature.
Because the frequency of toxoplasmosis among patients receiving co-trimoxazole prophylaxis had previously been shown to be low [9] and because the disease may develop years after the start of prophylaxis, we chose the nested case-control study design; careful attention was paid to reduce bias in patient selection, exposure definition, ascertainment of data, and disease detection to avoid the logistic and economic considerations of a randomized, controlled trial [10] .
Methods
Study population. In Spain, most HIV-infected patients use a public hospital located in their area of residence for inpatient and outpatient care. Our center is a 1000-bed academic institutional hospital that has a catchment area with 500,000 people. Inpatient and outpatient analyses, as well as any examination required throughout the course of disease, are free of charge for all patients; thus, no patients are subject to economic restrictions that might limit access to examinations that the physician considers to be appropriate. This case-control study included patients from our cohort of HIV-infected patients who underwent a diagnostic neuroimaging study between March 1993 and January 1997. Indications for the imaging studies were established by the patients' doctors, as they considered appropriate. During the study period, a total of 476 CTs and 568 MRIs were performed for 521 of our 1892 HIV-infected patients aged у14 years. Both case and control patients were identified from this diagnostic procedure framework.
Only the first examination of each patient was considered for this purpose, and the reference date for case and control patients was the date this first examination was carried out. Moreover, a complementary monitoring system was established to identify possible case patients through the charts of the infectious diseases service, hospital admission and discharge records, and emergency logs; all case patients identified in this way were also identified through CT or MRI reports.
Case and control patients. A case patient was an HIV-seropositive adult patient receiving co-trimoxazole prophylaxis who had been diagnosed with a first episode of toxoplasmic encephalitis during the study period. Toxoplasmic encephalitis was diagnosed by clinical findings (fever, neurological symptoms, or both), the appearance of у1 contrast-enhanced focal brain lesions on a CT or MRI, and response to sulfadiazine/pyrimethamine or clindamycin/pyrimethamine therapy. For patients who did not respond to antitoxoplasmic therapy, evidence of toxoplasmic encephalitis that was obtained by brain biopsy or autopsy was required. We considered that the presence of IgG antibodies specific to T. gondii was not essential for the diagnosis. However, serology for Toxoplasma was positive during or before the toxoplasmosis episode in all but 4 case patients. In 2 of these seronegative case patients, the diagnosis was made histopathologically. In the other 2 case patients, serology for Toxoplasma was positive 2 and 3 months after the diagnosis of toxoplasmosis.
We identified 32 eligible case patients, and all were available for the study. Eligible control patients for each case patient were HIVseropositive patients who did not have toxoplasmosis and who received co-trimoxazole prophylaxis. Two control patients were randomly selected for each case patient from the eligible control patients and were matched according to the following criteria: date of neuroimaging study (within 2 months), CD4 cell count ‫ע(‬ /L, within 3 months), and T. gondii serostatus (at any prior 6 30 ϫ 10 time for seropositive patients and within the last 6 months for seronegative patients).
For the 64 randomly selected control patients, the reasons for and results of neuroimaging study were as follows: HIV encephalitis, 9 patients; progressive multifocal leukoencephalopathy, 9; primary CNS lymphoma, 7; CNS tuberculosis, 5; CNS cryptococcosis, 5; cytomegalovirus encephalitis, 4; varicella-zoster virus meningoencephalitis, 1; purulent meningitis, 1; brain abscess due to Rhodococcus equi, 1; and headache, fever, seizures, or transient neuropsychiatric symptoms with no identifiable neurological disease, 22 .
Data collection. Two physicians retrieved data from the clinical charts and recorded the information on a structured form. Discrepancies between their assessments were solved by the patient's attending staff and in some instances by directly asking the patient, particularly regarding compliance with co-trimoxazole prophylaxis. The variables recorded included demographic features, risk factors for HIV infection, prior AIDS-defining illnesses, diagnostic criteria for toxoplasmosis, serology for Toxoplasma (detection of IgG antibodies specific to T. gondii in serum by commercially available ELISA), CD4 cell count, antiretroviral therapies, prophylaxis, and treatment of opportunistic infections. Frequent vomiting (more than once a day) and diarrhea (13 times a day), which are possible causes of reduced absorption, were also recorded. Data concerning date, duration, dose, and compliance with co-trimoxazole, rifampin, and antiretroviral therapies in the 6 months before the neuroimaging study were carefully recorded.
Co-trimoxazole prophylaxis was defined as co-trimoxazole prescribed at any dose for у3 weeks before the neuroimaging study. We deemed ineligible all patients who had completely abandoned prophylaxis for at least the last month. Co-trimoxazole prophylaxis was classified into low doses and high doses. We considered a dose of !4 DS tablets per week or its equivalent (8 SS tablets per week) to be a low dose and a dose of 14 DS tablets per week to be a high dose. Thus, 2 of the 5 regimens that our patients received were included in the low-dose category (3 DS tablets per week and 7 SS tablets per week), and the remaining 3 were included in the high-dose category (7, 6 , and 5 DS tablets per week). These doses of co-trimoxazole refer to the doses prescribed by the physician, independently of compliance on the part of the patient.
Compliance was divided into 3 categories: good, when the patient failed to take !20% of the prescribed treatment; bad, when the patient failed to take between 20% and 50% of the prescribed treatment; and very bad, when 150% of the prescribed treatment was neglected. For conditional logistic regression, bad and very bad compliance were recoded as bad compliance. The decision to group the data in this way was made before beginning collection of data.
The clinical indication for administering rifampin was treatment of tuberculosis in all except 2 patients: 1 case patient and 1 control patient who received rifampin as prophylaxis for tuberculosis.
Statistical analysis. All data were double-entered into a computer and verified for accuracy. When appropriate, the McNemar x 2 test and a conditional logistic regression model were used for paired 2 : 1 bivariate comparisons. ORs were applied to estimate relative risk. Conditional logistic regression was used to calculate the OR with exact 95% CIs and to adjust for potential confounders [11] . Because protective efficacy is defined as 1 minus the risk ratio in a cohort study and in a case-control study, the OR is an estimator of the risk ratio; therefore we estimated the protective efficacy of high doses of co-trimoxazole compared with that of low doses of co-trimoxazole for toxoplasmic encephalitis as 1 minus the OR [12] . Stratified analysis was used to compare the effect of rifampin exposure between patients receiving high and low doses of cotrimoxazole and the effect of co-trimoxazole doses between patients exposed and not exposed to rifampin. 
Results
There were no significant differences between case and control patients in terms of age, sex, route of HIV infection, presence of previous AIDS-defining illness, presence of previous P. carinii pneumonia, duration of co-trimoxazole prophylaxis, or use of antiretroviral therapy ( ). After adjusting for dose of co-trimoxa-P = .020 zole and compliance with co-trimoxazole prophylaxis, it remained stable (OR, 3.38; 95% CI, 1.08-10.61) and statistically significant (  ; table 3 ). The matched OR for bad com-P = .036 pliance with co-trimoxazole prophylaxis was 2.62 (95% CI, 1.07-7.01; ). After adjusting for dose of co-trimoxazole P = .026 and exposure to rifampin, the matched OR for compliance with co-trimoxazole prophylaxis was not statistically significant (  ; table 4 ). P = . 18 For patients receiving rifampin, the ORs for low doses of co-trimoxazole was 10.83 (95% CI, 1.77-84.36; ), P = .0064 whereas for patients not receiving rifampin, it was 3.63 (95% CI, 0.95-17.29;
). For patients receiving high doses of P = .055 co-trimoxazole, the OR for rifampin exposure was 1.41 (95% CI, 0.15-11.11; ), whereas for patients receiving low P = .55 doses of co-trimoxazole, the OR for rifampin exposure was 4.17 (95% CI, 1.28-14.29;
). P = .013
Discussion
This study showed that HIV-seropositive patients receiving a prophylactic dose of co-trimoxazole of!4 DS tablets per week had a higher risk of developing toxoplasmic encephalitis than did HIV-seropositive patients receiving 14 DS tablets of cotrimoxazole per week (estimated protective efficacy for high doses, 89%). Other risk factors for toxoplasmosis were rifampin therapy and bad compliance with co-trimoxazole prophylaxis. When adjusted by other variables, the increased risk for low ); matched P = .020 OR for rifampin exposure that was adjusted for dose of and compliance with co-trimoxazole prophylaxis: 3.38 (95% CI, 1.08-10.61;
). P = .036 doses of co-trimoxazole (9-fold) and rifampin exposure (3-fold) remained significant, whereas compliance with co-trimoxazole prophylaxis ceased to be significant.
Convincing evidence of the efficacy of co-trimoxazole as prophylaxis for toxoplasmic encephalitis has been provided by Carr et al. [9] . These investigators found that at a median follow-up of 288 days, none of the patients seropositive for T. gondii who were receiving prophylaxis with 4 DS tablets of cotrimoxazole per week developed toxoplasmic encephalitis, compared with 12 (33%) of 36 seropositive patients who were receiving pentamidine prophylaxis ( ). The dose of P = .008 co-trimoxazole that they used is not frequently prescribed and was intermediate between our high and low doses. There are few reliable data in the literature concerning the efficacy of the various doses of co-trimoxazole for the prevention of toxoplasmosis.
In a recent meta-analysis [4] including 22 randomized, controlled trials, a subgroup was established to estimate the prophylactic effect of different doses of co-trimoxazole (low, 1 DS tablet 3 times a week or 1 SS tablet daily; high, 1 DS tablet daily) versus aerosolized pentamidine. The risk ratio for toxoplasmic encephalitis in an intention-to-treat analysis was not significantly different between low and high doses of co-trimoxazole or between co-trimoxazole and pentamidine prophylaxis. In addition to the problems inherent to meta-analyses, with CIs that are too wide to permit definitive conclusions, we believe that there are some considerations that make it difficult to derive conclusions about the efficacy of high and low doses of co-trimoxazole for prevention of toxoplasmosis. Many patients had negative toxoplasma serology or CD4 cell counts 1 /L; thus, their risk for developing toxoplasmosis was 6 100 ϫ 10 low. Follow-up time was short; in more than one-half of the trials, it lasted !13 months. However, for patients receiving prophylaxis, the risk of presenting toxoplasmosis is probably greatest after this interval. In our study, the mean duration of co-trimoxazole prophylaxis for the patients who developed toxoplasmosis was 19.2 months.
In previously reported trials [8, [13] [14] [15] [16] [17] [18] [19] [20] [21] , most toxoplasmosis events in patients randomized to receive co-trimoxazole prophylaxis occurred after treatment was discontinued because of intolerance and therapy was switched to aerosolized pentamidine. In the intention-to-treat analysis, this change to a drug ineffective against toxoplasmic encephalitis may have resulted in underestimation of the efficacy of co-trimoxazole when compared with aerosolized pentamidine and underestimation of high doses of co-trimoxazole when compared with low doses (if high doses are more toxic than low doses).
We do not know what the minimal effective chemoprophylactic dose of co-trimoxazole is. Attaining a sufficient concentration of the drug within the CNS may be an additional problem in the prevention of toxoplasmosis. In the absence of meningeal inflammation, CSF penetration has been calculated to be 18% for trimethoprim and 12% for sulfamethoxazole [22] . It is reasonable to think that if co-trimoxazole concentrations are reduced because of interactions with rifampin or if compliance is not good, the efficacy of prophylaxis will be diminished, particularly when low doses, closer to the minimum effective dose, are given. On the other hand, although it has been suggested that alternate-day regimens may be less toxic than daily regimens [3] , we believe that daily dosing may be easier for patients to remember than dosing 3 times a week and that the consequences of a single missed dose are probably greater with intermittent dosing, as suggested by Kovacs [23] .
The finding that rifampin may reduce the efficacy of cotrimoxazole prophylaxis has not been previously described. Rifampin is a potent inducer of the hepatic microsomal system and thus gives rise to clinically important interactions when combined with other drugs. Rifampin decreases the plasma half-life of dapsone by 22%-83% [24] . Rifabutin significantly decreases the area under the concentration-versus-time curve of trimethoprim [25] . The effect of rifampin on the pharmacokinetics of trimethoprim-sulfamethoxazole is not known. Rifampin is a more potent inducer of the hepatic microsomal system than is rifabutin, and its effect on the decrease of cotrimoxazole components may be more important than those of rifabutin. A study comparing plasma concentrations of trimethoprim-sulfamethoxazole in patients with and without exposure to rifampin is ongoing.
Although the randomized, controlled trial would appear to be the best method for studies of clinical therapeutics because it is designed to eliminate bias in the selection of patients, the administration of therapy, and the detection of outcomes, it has some limitations [26] , particularly for uncommon diseases. Our results may be more representative of those a physician is likely to encounter in clinical practice than of those of controlled trials, but they are on-treatment results. We established rigorous criteria for study inclusion, exposure definitions, and collection of data to reduce the potential bias of a case-control study. Case and control patients were matched by CD4 cell count and toxoplasma serology, 2 fundamental risk factors for toxoplasmosis. Moreover, the dates on which case and control patients received prophylaxis with co-trimoxazole and attended the hospital's outpatient clinic were similar. Therefore, they had similar possibilities of receiving antiretroviral therapy or other ancillary treatment for HIV infection, as well as being subject to other uncontrolled factors that could change with time.
Control patients were selected only from those with a neuroimaging study, and this restriction may also have prevented the possibility of detection bias for a disease whose clinical presentation is often nonspecific, especially in patients receiving prophylaxis [27] . Because the indication for neuroradiological study was independent of the prophylaxis prescribed, and because the illnesses that motivated the examination were not related to the dose of co-trimoxazole that the patients received, we do not believe that the neuroimaging criterion would result in selection bias. Ascertainment bias was reduced by blinding the observer who determined eligibility of the patients to the hypothesis.
One potential source of bias in our study resided in the fact that the co-trimoxazole dose depended on the individual treating physicians, who had a tendency to administer similar doses to all their patients. Although the experience of primary care physicians in the management of AIDS may be associated with patient survival [28] , we do not believe that our patients had a greater or lower risk of developing toxoplasmosis according to the treating physician because of factors other than the dose of co-trimoxazole that they received. In our hospital, only 7 staff physicians manage HIV-infected patients and decide what prophylaxis and antiretroviral treatment are administered. The experience of these physicians with follow-up of patients was similar; moreover, we observed that compliance with co-trimoxazole prophylaxis and antiretroviral treatment were similar for the different physicians (data not shown).
Another potential source of bias might be the assessment of compliance with co-trimoxazole prophylaxis. We cannot rule out that real compliance might be slightly lower than that recorded for case and control patients, although this circumstance would not affect the results. It is also possible that in daily clinical practice, patients developing toxoplasmosis would be more thoroughly interrogated than control patients as to their compliance with prophylaxis. If more case patients of bad compliance were detected in this way, there might be some bias, and the real OR would be lower than that found. If, on the other hand, some patients did not admit that they had developed an illness because of failure to take the prescribed medication, the real OR would be higher than that found. We think that in the overall analysis, small deviations in compliance with co-trimoxazole prophylaxis would not substantially affect the results of the study.
In summary, of the 5 different doses of co-trimoxazole used in this study, high doses appear to be more effective than low doses to reduce the risk of toxoplasmosis in HIV-infected patients who tolerate it, and rifampin may decrease the efficacy of co-trimoxazole. Although additional studies are needed to confirm these results, we consider that HIV-infected patients at higher risk of developing toxoplasmosis (i.e., highly immunodepressed with antibodies to Toxoplasma) should not receive doses lower than 4 DS tablets per week. Higher doses may be especially important for patients receiving concomitant rifampin treatment.
